Susan Hayes Culleton

Indeed.

OK, and I was joining the dots a little bit here in your piece.

So you said growth in the sector, namely the health care sector, is expected to be primarily driven by both the ageing population and people living longer is a good thing, like we want that to happen.

But then you said the growing prevalence of chronic conditions such as heart disease, cancer and diabetes.

And about halfway down then, you also point out another part of America's health care story is about inequality, poverty and the sort of lifestyle issues, smoking, alcohol abuse, opioid addiction, obesity and the lack of exercise or access to fresh food.

The reason I say I'm joining the dots here is that

I'm guessing what you're pointing towards is that poorer people are unhealthier and therefore it's both costly for them to be poorer and thus it is the subsequent element of this is that they also don't have the money to be healthier.

Well, I'd be very surprised if it's not.

And also it comes in under a sub-bullet point of affordability, which is probably going to be the number one issue as well.

Another thing that you've pointed out here is 12% of Americans are now on GLP-1 drugs.

That's one in eight people.

What's the word on the street about that?

Do you find that that is...

really helping put off certain diseases in the future like diabetes, etc.?

Is it becoming a cultural norm now?

How is that impacting health care, both present and future, do you think?

The worrying thing there, I find, is the analogy you've made between something like Ozempic and Regovi and a vaccine, because one takes a vaccine once and then their body produces the thing, the chemical that tells, like wards off that disease in the future, whereas something like this needs to be taken all the time.

That's right.

There could be a very unhealthy relationship there, I would think.

What I'm definitely hearing from you, Rana, is that there's a lot of problems.